| Distinct effects of pitavastatin and atorvastatin on lipoprotein subclasses in patients with Type 2 diabetes mellitus. | |
| | |
MedLine Citation:
|
PMID: 21244474 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIMS: Effects of pitavastatin and atorvastatin on the lipid profile and lipoprotein subclasses were compared in patients with Type 2 diabetes with dyslipidaemia. METHODS: Patients with Type 2 diabetes with hypercholesterolaemia and/or hypertriglyceridaemia were randomized to receive pitavastatin 2 mg (n = 16) or atorvastatin 10 mg (n = 15) for 6 months, and blood lipid and lipoprotein profiles and cholesterol and triglyceride contents of 20 lipoprotein subclasses, determined by high-performance liquid chromatography, were compared. RESULTS: At baseline, cholesterol in VLDL and LDL subclasses were increased equally in two groups of patients with diabetes as compared with normolipidaemic control subjects. As compared with baseline, serum levels of total cholesterol, LDL cholesterol, non-HDL cholesterol, LDL cholesterol:HDL cholesterol ratio and apolipoprotein B were decreased after 1, 3 and 6 months of treatment with atorvastatin and pitavastatin. Serum triglyceride levels were decreased after 1, 3 and 6 months of atorvastatin, but only at 3 months of pitavastatin. Serum HDL cholesterol was increased after 1, 3 and 6 months of pitavastatin, whereas HDL cholesterol was even decreased after 6 months of atorvastatin. Cholesterol levels of most VLDL and LDL subclasses were decreased equally in both groups. However, only pitavastatin increased cholesterol of medium HDL subclass. Serum triglyceride and triglyceride contents in VLDL and LDL subclasses were decreased only by atorvastatin. CONCLUSIONS: The impact on lipoprotein subclass profiles was different between pitavastatin and atorvastatin. It may be beneficial to determine lipoprotein subclass profile and select the appropriate statin for each profile in patients with diabetes with an additional cardiovascular risk such as low HDL cholesterol or hypertriglyceridaemia. |
| | |
Authors:
|
M Shimabukuro; M Higa; H Tanaka; T Shimabukuro; K Yamakawa; H Masuzaki |
Related Documents
:
|
21316934 - Phytosterols supplementation decreases plasma small and dense ldl levels in metabolic s... 7217414 - Behavioral and neurochemical effects of neonatal administration of monosodium l-glutama... 855814 - Level of education, level of income, and level of fatness in adults. 19268484 - Peptide yy: food for thought. 11448844 - Increased pyruvate flux capacities account for diet-induced increases in gluconeogenesi... 18641204 - Tea is the major source of flavan-3-ol and flavonol in the u.s. diet. |
Publication Detail:
|
Type: Comparative Study; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: Diabetic medicine : a journal of the British Diabetic Association Volume: 28 ISSN: 1464-5491 ISO Abbreviation: Diabet. Med. Publication Date: 2011 Jul |
Date Detail:
|
Created Date: 2011-06-15 Completed Date: 2011-09-14 Revised Date: 2011-10-27 |
Medline Journal Info:
|
Nlm Unique ID: 8500858 Medline TA: Diabet Med Country: England |
Other Details:
|
Languages: eng Pagination: 856-64 Citation Subset: IM |
Copyright Information:
|
© 2011 The Authors. Diabetic Medicine © 2011 Diabetes UK. |
Affiliation:
|
Second Department of Internal Medicine, Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan. shimabukuro38@gmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Anticholesteremic Agents / therapeutic use* Blood Glucose / drug effects Cardiovascular Diseases / blood, drug therapy* Cholesterol, HDL / blood Cholesterol, LDL / blood, drug effects* Diabetes Mellitus, Type 2 / blood, drug therapy* Diabetic Angiopathies / drug therapy*, metabolism Female Heptanoic Acids Humans Hypercholesterolemia / blood, drug therapy* Lipoproteins / blood Male Middle Aged Pyrroles Quinolines / therapeutic use* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Anticholesteremic Agents; 0/Blood Glucose; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Heptanoic Acids; 0/Lipoproteins; 0/Pyrroles; 0/Quinolines; 110862-48-1/atorvastatin; 147511-69-1/pitavastatin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: High oolong tea consumption predicts future risk of diabetes among Japanese male workers: a prospect...
Next Document: Cerebral infarction associated with transient visual loss in child with diabetic ketoacidosis.